Novo Nordisk raises 2026 full-year guidance for the second time, narrowing expected sales and profit decline to 0% to -6% from prior -12% to 0%, citing stronger GLP-1 diabetes and obesity drug sales.

Jin1023:59 04-08

Novo Nordisk raises 2026 full-year guidance for the second time, projecting adjusted sales and operating profit decline of 0% to -6% at constant exchange rates, driven by higher GLP-1 drug sales; Q2 adjusted operating profit was DKK 33.39 billion.